Antoon M. van Doornmalen

504 total citations
16 papers, 386 citations indexed

About

Antoon M. van Doornmalen is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antoon M. van Doornmalen has authored 16 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antoon M. van Doornmalen's work include Microtubule and mitosis dynamics (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). Antoon M. van Doornmalen is often cited by papers focused on Microtubule and mitosis dynamics (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). Antoon M. van Doornmalen collaborates with scholars based in Netherlands and United States. Antoon M. van Doornmalen's co-authors include Guido J.R. Zaman, Joost C.M. Uitdehaag, Rogier C. Buijsman, Jos de Man, Martine B.W. Prinsen, Jeroen A.D.M. de Roos, Jesse W.Y. Wat, Elma E.M.G. Loomans, Nicole Willemsen‐Seegers and Kiyoshi Yoshino and has published in prestigious journals such as PLoS ONE, Cancer Research and Annals of Oncology.

In The Last Decade

Antoon M. van Doornmalen

16 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antoon M. van Doornmalen Netherlands 10 196 112 64 50 50 16 386
Jos de Man Netherlands 13 262 1.3× 122 1.1× 64 1.0× 53 1.1× 25 0.5× 22 497
Shashikant Patel India 12 230 1.2× 177 1.6× 52 0.8× 8 0.2× 89 1.8× 29 467
Owen M. Wilkins United States 11 463 2.4× 194 1.7× 43 0.7× 34 0.7× 30 0.6× 18 658
Cynthia M. Rominger United States 10 522 2.7× 247 2.2× 30 0.5× 29 0.6× 10 0.2× 11 748
Branka Stancevic United States 8 428 2.2× 77 0.7× 74 1.2× 7 0.1× 113 2.3× 8 677
Bhaswati Sarcar United States 12 418 2.1× 142 1.3× 68 1.1× 11 0.2× 22 0.4× 19 675
Yoshikatsu Kanai Japan 5 430 2.2× 125 1.1× 27 0.4× 12 0.2× 52 1.0× 10 685
Yasmine Nadler United States 6 189 1.0× 144 1.3× 99 1.5× 9 0.2× 22 0.4× 6 345
Soumen Kahali United States 8 373 1.9× 92 0.8× 60 0.9× 7 0.1× 19 0.4× 9 539
Gengjie Yang United States 13 291 1.5× 289 2.6× 17 0.3× 149 3.0× 62 1.2× 21 814

Countries citing papers authored by Antoon M. van Doornmalen

Since Specialization
Citations

This map shows the geographic impact of Antoon M. van Doornmalen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoon M. van Doornmalen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoon M. van Doornmalen more than expected).

Fields of papers citing papers by Antoon M. van Doornmalen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoon M. van Doornmalen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoon M. van Doornmalen. The network helps show where Antoon M. van Doornmalen may publish in the future.

Co-authorship network of co-authors of Antoon M. van Doornmalen

This figure shows the co-authorship network connecting the top 25 collaborators of Antoon M. van Doornmalen. A scholar is included among the top collaborators of Antoon M. van Doornmalen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoon M. van Doornmalen. Antoon M. van Doornmalen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Riel, Wilhelmina E. van, Martine B.W. Prinsen, Tessa J.J. de Bitter, et al.. (2022). Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology. 12. 953013–953013. 9 indexed citations
2.
Perez‐Pardo, Paula, Nicole Willemsen‐Seegers, Youri Adolfs, et al.. (2021). Pharmacological validation of TDO as a target for Parkinson’s disease. FEBS Journal. 288(14). 4311–4331. 19 indexed citations
3.
Man, Jos de, Antoon M. van Doornmalen, Nicole Willemsen‐Seegers, et al.. (2021). Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0. Frontiers in Immunology. 11. 609490–609490. 16 indexed citations
4.
Zaman, Guido J.R., Antoon M. van Doornmalen, Wilhelmina E. van Riel, et al.. (2020). Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget. 11(49). 4570–4581. 8 indexed citations
5.
Zaman, Guido J.R., Antoon M. van Doornmalen, Rogier C. Buijsman, et al.. (2019). Abstract 2221: Chemotherapy sensitivity of tumor cells from ascites of ovarian cancer patients: Relationship with immune status and clinical response. Cancer Research. 79(13_Supplement). 2221–2221. 2 indexed citations
6.
Zaman, Guido J.R., Antoon M. van Doornmalen, Suzanne J.C. van Gerwen, et al.. (2019). Abstract A044: A precision medicine platform to predict the clinical response to chemo- and immunotherapy for epithelial ovarian cancer. Molecular Cancer Therapeutics. 18(12_Supplement). A044–A044. 1 indexed citations
7.
Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2016). Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors. Molecular Cancer Therapeutics. 15(12). 3097–3109. 12 indexed citations
8.
Maia, Ana, Ute Boon, Aniek Janssen, et al.. (2015). Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Annals of Oncology. 26(10). 2180–2192. 93 indexed citations
9.
Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.. (2015). Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS ONE. 10(5). e0125021–e0125021. 16 indexed citations
10.
Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.. (2015). Abstract 3502: Selective targeting of CTNBB1-, KRAS- or MYC-driven cell growth by combinations of existing drugs. Cancer Research. 75(15_Supplement). 3502–3502. 1 indexed citations
11.
Doornmalen, Antoon M. van, et al.. (2014). High-Throughput Fluorescence-Based Screening Assays for Tryptophan-Catabolizing Enzymes. SLAS DISCOVERY. 19(9). 1266–1274. 38 indexed citations
12.
Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.. (2014). Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use. PLoS ONE. 9(3). e92146–e92146. 78 indexed citations
13.
14.
Loomans, Elma E.M.G., Antoon M. van Doornmalen, Jesse W.Y. Wat, & Guido J.R. Zaman. (2003). High-Throughput Screening with Immobilized Metal Ion Affinity-Based Fluorescence Polarization Detection, A Homogeneous Assay for Protein Kinases. Assay and Drug Development Technologies. 1(3). 445–453. 37 indexed citations
15.
Rotteveel, Francien T.M., Antoon M. van Doornmalen, & Marcel van Duin. (1995). sLex is not responsible for the interaction of sLex-positive memory T lymphocytes with E-selectin.. PubMed. 86(1). 34–40. 5 indexed citations
16.
Kuijpers, Will H. A., et al.. (1994). In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer.. PubMed. 54(13). 3479–86. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jos de Man Breakdown of academic impact, for papers by Shashikant Patel Breakdown of academic impact, for papers by Owen M. Wilkins Breakdown of academic impact, for papers by Cynthia M. Rominger Breakdown of academic impact, for papers by Branka Stancevic Breakdown of academic impact, for papers by Bhaswati Sarcar Breakdown of academic impact, for papers by Yoshikatsu Kanai Breakdown of academic impact, for papers by Yasmine Nadler Breakdown of academic impact, for papers by Soumen Kahali Breakdown of academic impact, for papers by Gengjie Yang
Rankless by CCL
2026